Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development

Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the
Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer
Treatment and Accelerate Oncology Drug Development

BALTIMORE, Nov. 12 /PRNewswire-FirstCall/ -- Champions Biotechnology, Inc.
(OTC Bulletin Board: CSBR), an oncology drug development company with a
predictive preclinical platform aimed at accelerating the development and
enhancing the value of oncology drugs, has announced that two of its studies
regarding its application in oncology drug development and personalized
medicine have been selected for a poster and oral presentation at the upcoming
AACR-EORTC conference in Boston.

A poster will be presented by Dr. Elizabeth Bruckheimer, Champions' Vice
President for Scientific Operations, which will detail the Biomerk
Tumorgraft(TM) platform and its characterization. Together the results
demonstrate that by maintaining the fundamental genotypic features of the
original tumor along with the stromal and cancer stem cell components, the
Biomerk Tumorgraft enables identification of the most promising development
path for a compound in terms of indication, drug combination, and target
patient populations. The platform also has the potential to identify gene
pathways of response and resistance as well as prognostic molecular
biomarkers. The banking and characterization efforts are performed in
collaboration with South Texas Accelerated Research Therapeutics (START).

"The predictive power of the Biomerk Tumorgraft platform is very exciting,"
said Dr. Bruckheimer. "Application of our models to translational drug
development is demonstrating great promise in streamlining the development
path of our biotech and pharma partners by giving them a more focused,
accelerated and higher probability translational path in clinical trials.
Additionally, we are using our platform to build our own oncology pipeline
which we expect to yield improved clinical development success rates. We
believe that this platform will continue to change the way in which oncology
drugs are developed, and oncology patients are treated."

In collaboration, Dr. Manuel Hidalgo, Professor of Oncology at the Universidad
CEU San Pablo, Director of the Centro Integral Oncologia "Clara Campal" and
Director of the Clinical Research Program at CNIO all in Madrid, Spain and
Champions' Chief Scientist will present data regarding prolonged clinical
responses from Tumorgraft recommended treatments in patients with refractory
advanced cancer, and the ability of the Tumorgraft platform to discover novel
predictive biomarkers. He will show the correlation between Tumorgraft
response in mice and clinical activity in patients, demonstrating a perfect
correlation of sensitivity and response.

Data Presentations:

-- From Mice to Men: Guiding Cancer Treatment through Personalized
Tumorgraft(TM) Models Results in Prolonged Clinical Responses in
Patients with Refractory Advanced Cancers and Discovery of Novel
Predictive Biomarkers will be presented on Tuesday November 17th from
4:30 - 5:30 PM during the Proffered Paper Session.

-- Establishment and Characterization of Primary Human Biomerk Tumorgraft
Models: Application to Oncology Drug Development will be presented on
Monday November 16th from 12:30 - 2:30 PM and 5:30 - 7:30 PM during
the
poster session (Abstract #A25).

For more information regarding Champions Biotechnology's growing business and
recent news, please visit www.championsbiotechnology.com.

About Champions Biotechnology, Inc.
Champions Biotechnology, Inc. is engaged in the development of advanced
preclinical platforms and tumor specific data to enhance and accelerate the
value of oncology drugs. The Company's Preclinical Platform is a novel
approach based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological characteristics of
the original human tumor. Early studies suggest that unlike traditional
xenografts, these Tumorgrafts closely reflect human cancer biology and their
response to drugs is predictive of clinical outcomes in cancer patients.
Champions Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic candidates. As
drugs progress through early stage development, the Company plans to sell,
partner or license them to pharmaceutical and/or biotechnology companies, as
appropriate. The Company also offers its predictive preclinical platform and
tumor specific data to physicians for personalized patient care and to
companies for evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery.
www.championsbiotechnology.com
www.personalizedcancertreatment.com

This press release contains "forward-looking statements" (within the meaning
of the Private Securities Litigation Act of 1995) that inherently involve risk
and uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect," "anticipate," "plan,"
and similar expressions to identify forward-looking statements. One should not
place undue reliance on these forward-looking statements. The Company's actual
results could differ materially from those anticipated in the forward-looking
statements for many unforeseen factors. See Champions Biotechnology's Form
10-K for the fiscal year ended April 30, 2009 for a discussion of such risks,
uncertainties and other factors. Although the Company believes the
expectations reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity, performance or
achievements may not meet these expectations. The Company does not intend to
update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.

CONTACT:
The Investor Relations Group, Inc.
James Carbonara
+1-212-825-3210

SOURCE Champions Biotechnology, Inc.

James Carbonara, The Investor Relations Group, Inc., +1-212-825-3210